Potential FDA Approval Just Around the Corner for a Blockbuster Product (Mino-Lok) With Billion-Dollar Market Estimates

Potential FDA Approval Just Around the Corner for a Blockbuster Product (Mino-Lok) With Billion-Dollar Market Estimates

Citius Pharma (CTXR) Brings More Experts on Board

CTXR looking ready to hit the gas

Good day everyone,

We are continuing our coverage of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company that develops and commercializes critical care products.

Current price $1.26 per share
Outstanding shares (est.) 45.19M
Float (est.) 24.53M
Insider ownership 39.08%

Potential near term to midterm catalysts for CTXR shares:

Publishing of date from the Mino-Lok phase III clinical trial
More shares being purchased by institutions
Any further developments on the NoveCite stem cell treatment for covid 19

When we last reported to you on CTXR, in early July, we said:

“The case for CTXR shares is simple. Their market cap of $55 million seems too low for a company with potential FDA approval just around the corner for a blockbuster product (Mino-Lok) with billion-dollar market estimates, and a prospective Covid 19 treatment on the horizon.” That statement is still true today.

CTXR is building momentum in the development of its products.
Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. He strengthens the position for Citius as a developer of adjunctive cancer therapies (Mino-Lok and Mino-Wrap) and the NoveCite induced allogeneic mesenchymal stem cell program. Dr. Czuczman has impressive credential and we have linked a press release describing them below: https://finance.yahoo.com/news/citius-pharmaceuticals-brings-myron-czuczman-124700331.html

In addition to the hire of Dr. Czuczman, the company announced the formation of the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to further the development of NoveCite. The advisory board consists of three doctors with extensive expertise in pulmonary disorders and stem cell treatments. Again, we have linked a press release that details their qualifications. https://finance.yahoo.com/news/citius-pharmaceuticals-forms-scientific-advisory-143000331.html

We wondered why CTXR is making these moves now. Why after a couple years of Mino-Lok development and just a couple months into their license agreement with Novellus for NoveCite?

We don’t know, we can just speculate. Mino-Lok is in its final stages of development, nearing the end of its phase III clinical trial. Dr. Czuczman can provide helpful medical guidance, for the company, regarding FDA clearance and product marketing.

CTXR has a six-month exclusive license with Novellus for the development of NoveCite. The creation of the advisory panel could help to accelerate that process. Remember, on June 26, the FDA acknowledged that the company could apply for fast track designation and provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to progress with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

2 Wall Street analysts have issued ratings and price targets for Citius Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 334.78%. The high price target for CTXR is $7.00 and the low-price target for CTXR is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”

CTXR has a tiny share structure with high insider and institutional ownership. These are traits that can accelerate a stock gain trend.

As the chart linked below indicates, CTXR shares have been above their 50 DMA and 200 DMA of $1.13 and $.84 respectively for a few weeks. The company shares are leading their SMA 50 and SMA 200 by 12.4% and 50.6% respectively indicating the shares may be trending. These data could indicate a bullish outlook for CTXR shares.

We will be back with more on CTXR soon,

The Traders News Group


Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address

What do we use your information for?

When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies only to information collected through our website and not to information collected offline.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.


Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated ten thousand dollars cash via bank wire by venado media llc for this weeks updated coverage of ctxr. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.